Previous 10 | Next 10 |
Alkermes (NASDAQ: ALKS ) is scheduled to announce Q4 earnings results on Thursday, February 13th, before market open. The consensus EPS Estimate is $0.66 (+94.1% Y/Y) and the consensus Revenue Estimate is $404.5M (+28.1% Y/Y). Over the last 2 years, ALKS has beaten EPS estimates 75% ...
DUBLIN , Feb. 6, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on Thursday, Feb. 13, 2020 , to discuss the company's fourth quarter and year-end 2019 financial results. Management will also disc...
AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Shares of Alkermes (NASDAQ: ALKS) closed almost 11% higher in Wednesday trading on news that Biogen (NASDAQ: BIIB) had successfully defended its patent on its multiple sclerosis drug Tecfidera. That's a win for Alkermes because it developed a second-generation version of Tecfidera called...
Quick Take Passage Bio ( PASG ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing genetic treatments for monogenic (single gene) central nervous system [CNS] health conditions. PASG is at pre-clinical stage...
Investment Thesis Objective: Wealth-building of an always fully-invested portfolio via repeated near-term (weeks or months) capital gains from careful, diversified, odds-on issue selection and timely price opportunity capture. This article deals, by comparisons, with ALKS market-price ques...
DUBLIN , Jan. 28, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) seeking approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophr...
DUBLIN , Jan. 8, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT ( 12:00 p.m. ET / 5:00 p.m. GMT ) from the...
Alkermes ( ALKS ) is a poster child for the difficulties of investing in early stage biotech. It has been successful over the years in getting FDA approvals and big pharma licensing agreements for a variety of significant therapies, however it has never been a successful investment vehicle. ...
DUBLIN , Nov. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, Dec. 3, 2019 at 8:00 a.m. ET ( 1:00 p...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...